5/11/2014 1 BELGIAN CONSENSUS MEETING on TRAVEL MEDICINE June 20, 2014 Belgian Scientific Study Group on Travel Medicine Pr. A. Van Gompel (ITG) Pr. F. Jacobs (Hôp. Erasme, ULB) Pr. P. Lacor (UZ-Brussel) Dr. Ph. Leonard (CHU-ULg) Pr. W. Peetermans (U.Z. - K.U.Leuven) Pr. S. Callens(UZ.- U.Gent) Dr. S.Quoilin (iph.fgov.be) Dr.P. Soentjens (Belgian Defence) Pr. B. Vandercam (CHU. St. Luc, UCL) Pr. Y. Van Laethem (CHU. St. Pierre, ULB) PART 2 version 05/11/2014
67
Embed
BELGIAN CONSENSUS MEETING on TRAVEL MEDICINE … · 5/11/2014 1 BELGIAN CONSENSUS MEETING on TRAVEL MEDICINE June 20, 2014 Belgian Scientific Study Group on Travel Medicine Pr. A.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
5/11/2014
1
BELGIANCONSENSUS MEETINGon TRAVEL MEDICINE
June 20, 2014
Belgian Scientific Study Group on Travel
Medicine
Pr. A. Van Gompel (ITG)Pr. F. Jacobs (Hôp. Erasme, ULB)
Pr. P. Lacor (UZ-Brussel) Dr. Ph. Leonard (CHU-ULg)
Pr. W. Peetermans (U.Z. - K.U.Leuven) Pr. S. Callens(UZ.- U.Gent) Dr. S.Quoilin (iph.fgov.be)
Dr.P. Soentjens (Belgian Defence)Pr. B. Vandercam (CHU. St. Luc, UCL)
Pr. Y. Van Laethem (CHU. St. Pierre, ULB)PART 2 version 05/11/2014
5/11/2014
2
REPORTBELGIAN CONSENSUS MEETING on TRAVEL MEDICINE
June 20, 2014 – PART 2
2014
• The consensus meeting was chaired by A. Van Gompel• Secretary of the meeting was Y, Van Laethem• A preliminary PowerPoint, prepared by A. Van Gompel,
was presented• The discussion and recommendations of the
meeting are included in this finale presentation.• The ESSENTIAL SLIDES (pdf-version) & the
CONSENSUS BROCHURE (in Dutch and French) highlighting the proposals for changes will been sent to all participants. May be used for teaching.
• These documents will serve as a proposal for approval by the governmental Belgian Health Council – section Vaccinations, on 26-06-2014
• Responsable final redaction : A. Van Gompel
PART 1• 1.a - Vaccination for Yellow Fever• 1.b - Malaria
PART 2• 2.A - Other vaccinations• 2.B - TD, other infections, …., • 2.C - VARIA
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
2014
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
5/11/2014
5
2014
5/11/2014
6
2014
Primovaccinatie met dTp(a) ? In de bijsluiter wordt de primovaccinatiemet het dTp(a)-vaccin niet vermeld.Ook de aanbeveling van de HogeGezondheidsraad vermelden daaroverniets.Een studie uit 2007 onderzocht bijvolwassenen ouder dan 40 jaar die devoorbije 20 jaar geen tetanus of difterievaccinhadden gekregen of waarvan devaccinatiestatus onbekend was, de efficiëntievan dTp(a) en dTp(a)-IPV-vaccins.Eén maand na de toediening van 3 dosissen,bedroeg het niveau van beschermendeantistoffen 99%. Bij gebrek aan dT kan dTp(a) dus worden gebruikt voor primovaccinatie. Indien ook bescherming tegen polio nodig is, kan dTp(a)-IPV gebruikt worden
Primovaccination avec le dTp(a) ?
Ni la notice, ni les recommandations duConseil Supérieur de la Santé ne mentionnentla possibilité d’une primovaccinationavec le dTp(a).Cependant, une étude publiée en2007 a montré chez 99% des vaccinésl’obtention de taux séroprotecteurscontre le tétanos et la diphtérie après uneprimovaccination à l’aide du dTp(a) (3doses), chez des adultes de plus de 40ans (en absence de données vaccinalesou avec un dernier rappel datant de plusde 20 ans).En cas d’indisponibilté du dT, par exemple lors d’une rupture de stock, l’administration du dTp(a) pourrait donc être utilisé en primovaccination. En cas de nécessité d’une protection contre la poliomyélite, dTp(a)-IPV peut être utilisé,
Theeten H et al, Primary vaccination of adults with reduced antigen-content diphtheria-tetanusacellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Current medical research and opinion. Vol. 23, n° 11, 2007 : 2729-2739.
2014
5/11/2014
7
POLIO
2014
POLIO
• SEARO/WHO South-East Asia: Press release 26 March 2014 :
WHO South-East Asia Region certified polio-free
2014
• WHO Polio Eradication Initiative http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
• …… declared the international spread of wild poliovirus in 2014 a Public Health Emergency of International Concern (PHEIC).
• …… the Committee’s advice – for ‘States currently exporting wild
polioviruses’ and – for ‘States infected with wild poliovirus but not
currently exporting’ ….. • …. issued them as Temporary
Recommendations under the IHR (2005) to reduce the international spread of wild poliovirus, effective 5 May 2014
• reassessment of this situation in 3 months
WHO 05-05-2014
ECDC 28/05/2014
5/11/2014
11
(= PHEIC).
ECDC 28/05/2014
since august 2014 also Equatorial Guinea
2014
5/11/2014
12
Imovax Polio ®
Revaxis ® & Boostrix IPV ® =also Polio
Clearly mention that this is polio-vaccination
2014
5/11/2014
13
Travel Vaccinations
1. Hepatitis A 2. Hepatitis B 3. Typhoid fever4. Rabies5. Meningococcal meningitis6. Japanese encephalitis7. TBE - FSME
2014
5/11/2014
14
HEPATITIS A
Immunodepressed traveler should – if possible - receive the complete series
(2 / 3 doses) before leave(+ antibodytiter)
2014
5/11/2014
15
Results: • The final study population consisted of
53 patients treated with • TNFi (n 15),TNFi & MTX (n 21) or MTX (n 17)
months after the 1st dose % of the patients that had attained seroprotection
1 10%6 33%months after the 2nd dose1 83%6 72%
at month 24 86%
Conclusions: • Two doses of hepatitis A vaccine at a 6-
month interval provided protection for most immunosuppressed RA patients.
• A single dose does not seem to afford sufficient protection to this group of patients.
5/11/2014
16
HEPATITIS B
Immunodepressed …..
2014
5/11/2014
17
2014
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
INFLUENZA
2014
5/11/2014
18
5/11/2014
19
TYPHOID FEVER
2014
Cochrane 2014
5/11/2014
20
Cochrane 2014
IDSA 2012 conference poster 251 2012
5/11/2014
21
2014
2012
5/11/2014
22
MENINGOCOCCAL MENINGITIS
2014
Promedmail 20 May 2014• The new vaccine MenAfriVac® is manufactured by
Serum Institute of India Ltd. and was developed for the meningitis belt through the Meningitis Vaccine Project, a partnership between WHO and PATH, funded by the Bill & Melinda Gates Foundation.
• …… since the introduction of the meningococcal A conjugate vaccine in countries of the African meningitis belt in 2010, the WHO noted a decrease in the number of cases of meningitis; in fact, the number of cases in 2013 was the lowest recorded during the epidemic season in the last 10 years (http://www.who.int/csr/don/2013_06_06_menin/en/).
• In addition, Neisseria meningitidis serogroup A was noted to be no longer the predominant pathogen.
5/11/2014
23
Lancet 2014
CID_13
5/11/2014
24
LID 2012
2014
5/11/2014
25
2014
RABIES
2014
5/11/2014
26
2013
From 31- 05 - 2013 on:no booster after 1 year or later is advisedanymore for at least 20-30 yearsafter the basic series of 3 shots (1-7-21/28) in persons with normal immunity
2012
Accelerated schedule off label
• Accelerated schedules (D1, D4, D8) • not licenced = off label• To be discussed with the client
The percentages of subjects with RVNA levels ≥ 0.5 IU/mL at7 days after the last active vaccination were
100% (R/JE-Acc) and 99% (R-Conv).
2014
5/11/2014
29
As expected, a faster decrease in RVNA antibody titers was observed inthe accelerated group than in the 2 conventional schedule groups(Figure 2A).
Irrespective of vaccination regimen, strong short-term immune responsesup to day 57 were observed, with percentages of subjects with adequateantibody titers above 95% at all time points in all groups as soon as 2weeks after the first vaccination (Figure 2B).
2014
2014
5/11/2014
30
2014
2014
5/11/2014
31
2014
TO DOWNLOAD http://www.sbimc.org/1-Rabies-Soentjes.pdf
5/11/2014
32
TO DOWNLOAD http://www.sbimc.org/1-Rabies-Soentjes.pdf
Future
accelerated & intradermal rabies vaccination
(Soentjes et al. ,,,)
2014
5/11/2014
33
JAPANESE ENCEPHALITIS
2014
Accelerated schedule off label
• Accelerated schedules (D1, D8) • not licenced = off label• To be discussed with the client
• 2013 : Ixiaro from the age of 2 months on• CISTM 13 Maastricht : “Based on modeled
data, we expect protection to last for at least 4 years in 95% of vaccinees”
2013
Japanese encephalitis (Ixiaro®)
• The standard scheme requires 2 injections, separated by one month. Afterwards, the traveler remains boostablewhich means that a booster dose can be given after 12-24 months – (later boosters ? 3-5 years ?)
• When the patient was vaccinated with Jevax® previously the consensus meeting gives the advice to use two doses of Ixiaro® when Jevax® dates from five years back or more.
2011
5/11/2014
40
TBE FSME
2014
2013 2014
5/11/2014
41
2014
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
5/11/2014
42
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
2014
5/11/2014
43
PART 1• 1.A - Vaccination for Yellow Fever• 1.B - Malaria
PART 2• 2.A - Other vaccinations• 2.B - TD, other infections, …., • 2.C - VARIA
2014
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
2014
5/11/2014
44
Quid role in travel medicine ?
2013
Racecadotril Tiorfix& Aanpak in de eerste lijn van acute diarree bij het kind
RECENTE INFORMATIE OKTOBER 2012
• Racecadotril (Tiorfix®; hoofdstuk 3.6.4.) is een antidiarreïcum dat in het buitenland gecommercialiseerd is sinds 1993;
• het gaat om een inhibitor van de enkefalinasen (enzymen verantwoordelijk voor de afbraak van bepaalde endogene opioïden, de enkefalines), vooral ter hoogte van de darmmucosa.
• Racecadotril heeft een perifere werking met vermindering van de intestinale hypersecretie.
• De posologie vermeld in de Samenvatting van de Kenmerken van het Product (SKP) is bij volwassenen 100 mg, gevolgd door 100 mg 3 maal per dag, en bij het kind ouder dan 3 maanden 1,5 mg/kg, 3 maal per dag.
• De voornaamste ongewenste effecten zijn secundaire obstipatie en hoofdpijn.• Racecadotril is gecontra-indiceerd bij aanwezigheid van koorts en bloederige of
slijmerige ontlasting (acute dysenterie). • In de vergelijkende studies met loperamide (een opiaatderivaat en remmer van de
intestinale peristaltiek) hadden beide behandelingen een gelijkaardige doeltreffendheid, waarbij de diarree-episode slechts met een paar uur verkortte.
• Men moet voor ogen houden dat de aanpak van acute diarree vooral gebaseerd is op rehydratiemaatregelen, en dat antidiarreïca slechts een zeer beperkte plaats hebben, vooral bij jonge kinderen. De vormen voor gebruik bij kinderen zijn voorschriftplichtig.
2013
5/11/2014
45
Le racécadotril ( Tiorfix®; chapitre 3.6.4.) est un antidiarrhéique commercialisé à l’étranger depuis ‘93;
• il s’agit d’un inhibiteur des enképhalinases (des enzymes responsables de la dégradation de certains opioïdes endogènes, les enképhalines) particulièrement au niveau de la muqueuse intestinale.
• Le racécadotril exerce une activité périphérique en diminuant l’hypersécrétion intestinale.
• La posologie mentionnée dans le Résumé des Caractéristiques du Produit (RCP) est chez l’adulte de 100 mg suivie de 100 mg 3 x par jour, et chez l’enfant âgé de plus de 3 mois de 1,5 mg/kg, 3 x par jour.
• Ses principaux effets indésirables consistent en de la constipation secondaire et des céphalées.
• Le racécadotril est contre-indiqué en présence de fièvre et de selles glaireuses ou sanglantes (dysenterie aiguë).
• Dans les études comparatives avec le lopéramide (un dérivé des opiacés, freinateur du transit intestinal), les deux traitements avaient une efficacité comparable, ne diminuant que de quelques heures l’épisode diarrhéique.
• Il faut garder à l’esprit que la prise en charge de la diarrhée aiguë repose avant tout sur des mesures de réhydratation, et que les antidiarrhéiques n’ont qu’une place très limitée, en particulier chez les jeunes enfants. Les formes de racécadotril destinées à l’usage chez l’enfant sont soumises à prescription.
2013
Chikungunya
2014
5/11/2014
46
2014
Eurosurveillance, Volume 19, Issue 28, 17 July 2014
2014
5/11/2014
47
Dengue
New WHO map
2014
2014
5/11/2014
48
5/11/2014
49
Hajj
19/09 – 12/10 2014
2014
2014
5/11/2014
50
Kingdom of Saudi Arabia Ministry of Health
Health Regulations for travellers to Saudi Arabia for Umrah &
General advice for Mecca pilgrims -required/recommended vaccines• Vaccination with a tetravalent, conjugated ACYW135
meningococcal vaccine is required to obtain a visa.
• Available vaccines in Belgium: Nimenrix® and Menveo®
• The unconjugated 4-valent meningococcal vaccine is not available anymore in pharmacy (July 2013) – it might still be available in the travel clinics and be used in pilgrims
• It remains unclear if children till the age of 2 years are obliged to be vaccinated, but it correct to vaccinate also the little children – on the other hand, see further : children under 12 yrs are discouraged to come to Mecca.
2013 = 2014
5/11/2014
54
General advice for Mecca pilgrims -required/recommended vaccines• Incompletely vaccinated individuals should update
their vaccine status.• Vaccination against the seasonal flu is
recommended when available (around mid-September, the pilgrimage starts October 4th).
• Pneumococcal vaccine for the known risk groups• Hepatitis A vaccination is recommended,
depending on age and medical history.• For journeys exceeding 3 weeks stay, a
vaccination against typhoid fever may be advisable.
2013 = 2014
… & Mers
2014
5/11/2014
55
2014
2014
5/11/2014
56
2014
2014
5/11/2014
57
2014
Promedmail - Morocco 19-6-2014• Advice not to go on the Hadj … !!
5/11/2014
58
Because of the MERS-Cov : The Saudi Ministry of Health
recommends that people• aged over 65 years and • those with chronic diseases (e.g. heart disease, kidney disease,
respiratory disease, diabetes) and • pilgrims with immune deficiency (congenital and acquired), • malignant and • terminal illnesses, • pregnant women and • children aged under 12 years
planning to come for Hajj and Umra this year, to postpone the performance of the Hajj and Umra for their own safety.
2013
2014
5/11/2014
59
http://www.who.int/ith/updates/20140603/en/
2014
Ebola
2014
5/11/2014
60
2014
2014
5/11/2014
61
Schistosomiasis
Medasso-Headlines Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso-Headlines Conseils de santé pour voyageurs Edition 2012-2013
2014
2014
5/11/2014
62
CDCLetter EID sept 2014 In press
2014
5/11/2014
63
PART 1• 1.a - Vaccination for Yellow Fever• 1.b - Malaria
PART 2• 2.A - Other vaccinations• 2.B - TD, other infections, …., • 2.C - VARIA
2014
2014
5/11/2014
64
Deep Venous Thrombosis
Medasso-Headlines Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso-Headlines Conseils de santé pour voyageurs Edition 2012-2013
2014
2014
Itchy skin problems during travel
Medasso / ITG Gezondheidsadviezen voor reizigers Uitgave 2014-2015Medasso / IMT Conseils de santé pour voyageurs Edition 2012-2013
5/11/2014
65
2014 A division of “Outdoor Medicine” (Nl) in Belgiumwww.outdoormedicine.org & www.awls.be
Future links with travel medicine ? (cfr ISTM & Wilderness Medical Society in the US)
Commitment travel clinics waiting lists & capacity last
minute travelers ?
- Waiting time max 2 weeks ? - Ability to help as soon as
possible last minute travelers ?
2014
5/11/2014
66
Varia – NEW BOOKS Handboek vaccinatiesDeel B Infectieziekten
en vaccinaties
• Rudy Burgmeijer, Karel Hoppenbrouwers, Fons Van Gompel (red.)